Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Dass S. Vinay, Elizabeth P. Ryan, Graham Pawelec, et al.
Seminars in Cancer Biology (2015) Vol. 35, pp. S185-S198
Open Access | Times Cited: 1401

Showing 1-25 of 1401 citing articles:

NRF2 and the Hallmarks of Cancer
Montserrat Rojo de la Vega, Eli Chapman, Donna D. Zhang
Cancer Cell (2018) Vol. 34, Iss. 1, pp. 21-43
Open Access | Times Cited: 1314
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Judith A. Seidel, Atsushi Otsuka, Kenji Kabashima
Frontiers in Oncology (2018) Vol. 8
Open Access | Times Cited: 1183
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Miguel F. Sanmamed, Lieping Chen
Cell (2018) Vol. 175, Iss. 2, pp. 313-326
Open Access | Times Cited: 1183
A review of cancer immunotherapy toxicity
Lucy Boyce Kennedy, April K.S. Salama
CA A Cancer Journal for Clinicians (2020) Vol. 70, Iss. 2, pp. 86-104
Open Access | Times Cited: 1097
Kinase inhibitors: the road ahead
Fleur M. Ferguson, Nathanael S. Gray
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 5, pp. 353-377
Closed Access | Times Cited: 890
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Rong En Tay, Emma K. Richardson, Han Chong Toh
Cancer Gene Therapy (2020) Vol. 28, Iss. 1-2, pp. 5-17
Open Access | Times Cited: 630
Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification
Saranya Chidambaranathan Reghupaty, Paul B. Fisher, Devanand Sarkar
Advances in cancer research (2020), pp. 1-61
Open Access | Times Cited: 613
Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
Marco B.E. Schaaf, Abhishek D. Garg, Patrizia Agostinis
Cell Death and Disease (2018) Vol. 9, Iss. 2
Open Access | Times Cited: 515
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
Veronica Huber, Chiara Camisaschi, Angela Berzi, et al.
Seminars in Cancer Biology (2017) Vol. 43, pp. 74-89
Open Access | Times Cited: 505
Lung cancer immunotherapy: progress, pitfalls, and promises
Aritraa Lahiri, Avik Maji, Pravin D. Potdar, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 505
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity
Ashley V. Kroll, Ronnie H. Fang, Yao Jiang, et al.
Advanced Materials (2017) Vol. 29, Iss. 47
Open Access | Times Cited: 452
Mitochondria as playmakers of apoptosis, autophagy and senescence
Marianna Abate, Agostino Festa, Michela Falco, et al.
Seminars in Cell and Developmental Biology (2019) Vol. 98, pp. 139-153
Closed Access | Times Cited: 452
Next generation of immune checkpoint inhibitors and beyond
Julian A. Marin‐Acevedo, ErinMarie O. Kimbrough, Yanyan Lou
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 444
The dormant cancer cell life cycle
Tri Giang Phan, Peter I. Croucher
Nature reviews. Cancer (2020) Vol. 20, Iss. 7, pp. 398-411
Closed Access | Times Cited: 420
Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Daniel G. Coit, John A. Thompson, Mark R. Albertini, et al.
Journal of the National Comprehensive Cancer Network (2019) Vol. 17, Iss. 4, pp. 367-402
Open Access | Times Cited: 402
Synthetic lethality as an engine for cancer drug target discovery
Alan Huang, Levi A. Garraway, Alan Ashworth, et al.
Nature Reviews Drug Discovery (2019) Vol. 19, Iss. 1, pp. 23-38
Closed Access | Times Cited: 383
Interplay between Circadian Clock and Cancer: New Frontiers for Cancer Treatment
Gabriele Sulli, Michael T. Lam, Satchidananda Panda
Trends in cancer (2019) Vol. 5, Iss. 8, pp. 475-494
Open Access | Times Cited: 362
Notch as a tumour suppressor
Craig S. Nowell, Freddy Radtke
Nature reviews. Cancer (2017) Vol. 17, Iss. 3, pp. 145-159
Closed Access | Times Cited: 333
Immunosuppressive cells in tumor immune escape and metastasis
Yang Liu, Xuetao Cao
Journal of Molecular Medicine (2015) Vol. 94, Iss. 5, pp. 509-522
Closed Access | Times Cited: 328
Combine and conquer: challenges for targeted therapy combinations in early phase trials
Juanita Lopez, Udai Banerji
Nature Reviews Clinical Oncology (2016) Vol. 14, Iss. 1, pp. 57-66
Open Access | Times Cited: 328
Tumors induce de novo steroid biosynthesis in T cells to evade immunity
Bidesh Mahata, Jhuma Pramanik, Louise van der Weyden, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 309
Metal Drugs and the Anticancer Immune Response
Bernhard Englinger, Christine Pirker, Petra Heffeter, et al.
Chemical Reviews (2018) Vol. 119, Iss. 2, pp. 1519-1624
Open Access | Times Cited: 302
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets
Yan Tie, Fan Tang, Yuquan Wei, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 294
CRISPR in cancer biology and therapy
Alyna Katti, Bianca J. Diaz, Christina M. Caragine, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 5, pp. 259-279
Open Access | Times Cited: 288
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Matthias Pinter, Rakesh K. Jain
Science Translational Medicine (2017) Vol. 9, Iss. 410
Open Access | Times Cited: 275
Page 1 - Next Page

Scroll to top